Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III
This article was originally published in PharmAsia News
The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars.
You may also be interested in...
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
South Korea is making a strategic push to strengthen its vaccine capabilities, with a focus on COVID-19 and future pandemics and the aim of becoming a global development hub. But one expert told a recent meeting that these goals should not overshadow the government’s original aim of becoming self-sufficient for the national immunization program.
The International Vaccine Institute’s director general warns about COVID-19 vaccine distribution inequalities and its serious consequences, arguing the case for increased global coordination and responsibility for action to improve the situation.